Case report

A case of a prolactinoma resistant to dopamine agonists

Irene Vourliotaki1, Ingrid Elizabeth Bonapart1, Catherine Stamataki1, Eva-Maria Tsapakis2, Catherine Saridaki1

1Department of Endocrinology and Metabolism, Venizelio General Hospital, Iraklion, Crete, Greece, 2Institute of Psychiatry, London, UK

ABSTRACT
Dopamine agonists are the drugs of choice in the treatment of prolactinomas, the most common type of pituitary adenomas. However, up to 25% of prolactinomas do not respond to these drugs and alternative treatments have to be considered. We describe a 37-year old female with a microprolactinoma who, although having received all available formulations of dopamine agonists over a period of 11 years, did not respond either clinically—diminution of galactorrhea and restoration of her menstrual cycle—or hormonally through normalisation of the elevated prolactin levels. Throughout the same period, the size of the adenoma remained unchanged. While on high doses of dopamine agonists, the patient presented with side effects such as nausea, vomiting, orthostatic hypotension and tachycardia without any symptoms of psychosis. Therefore, either the dose of the dopamine agonists was not toxic enough for the mesolimbic dopaminergic pathway to be activated or the patient was dopamine-resistant in this pathway as well.

Key words: Dopamine agonists, Prolactinoma

INTRODUCTION
Dopamine agonists are usually effective in the treatment of prolactinomas, which represent the most common type of pituitary adenomas. By and large, these drugs result in normalisation of prolactin (PRL) levels as well as in a substantial reduction in tumour size.1,2 Some prolactinomas, however, do not respond to dopamine agonists and are considered to be resistant to this form of treatment. Resistance to dopamine agonists is defined as failure to normalise or reduce PRL levels or tumour size by ≥50%. We here present a patient with a prolactinoma resistant to all available dopamine agonist formulations.

PATIENT’S DESCRIPTION
A 37-year old woman, mother of two children, was referred to the Endocrinology Unit with a history of a microprolactinoma diagnosed 11 years earlier and 2 years following the birth of her second child. At the time, she presented with persistent galactorrhea and secondary amenorrhea. There was
I. VOURLIOTAKI, ET AL

no history of menstrual disorders prior to her second pregnancy. At the initial diagnosis, her PRL levels were in the range of 150-200 ng/ml, and an initial M.R.I. scan of the pituitary revealed a microadenoma located on the left lateral part of the anterior pituitary, measuring 8 mm at maximum diameter; there was no sellar enlargement or extrasellar extension. All other causes of hyperprolactinaemia were excluded, and there were no symptoms, signs or laboratory evidence of other pituitary hormonal deficiencies. Estradiol was found to be low normal (125 pmol/L, normal range 0.01-587), with normal gonadotropins and androgens. Personal and family history was unremarkable.

The patient was initially treated with dopamine agonists as follows: During the first four years of her illness, she was given a gradually increasing dose of bromocryptine up to a maximum of 15 mg per day. Usual doses for the treatment of prolactinomas range between 2.5 and 10 mg per day, and for Parkinson’s disease maximum doses may reach 60 mg per day. Over this time, amenorrhea and galactorrhea persisted and PRL plasma levels remained unchanged (150-200 ng/ml). However, the patient experienced significant side effects from this treatment, including orthostatic hypotension, tachycardia, nausea and vomiting and was consistently depressed. In addition, estradiol measured during the 4th year of treatment was 56 pmol/L (normal range 0.01-587 pmol/L), a value lower than the one obtained 4 years previously, whereas serum androgen levels were still normal. Luteinizing Hormone (LH) was low-normal (1.09 IU/L, normal range 1.1-11.6 IU/L) while Follicular Stimulating Hormone (FSH) was normal (9.29 IU/L, normal range 2.8-11.3 IU/L). No other pituitary hormones abnormalities were noted. On account of the side effects and lack of clinical and biochemical improvement by the end of the 4th year from diagnosis, the patient was switched to quinagolide, another second-line dopamine agonist, gradually reaching a maximum dose of 750 µg per day (usual dose for prolactinomas 75-150 µg per day. Quinagolide was better tolerated, but it also failed to reduce the elevated PRL levels. Two years later she was prescribed cabergoline up to 2.5 mg/d (usual dose for prolactinomas 0.5 – 1.0 mg weekly). PRL levels before cabergoline administration were 185 ng/ml. Upon referral to our Unit, the patient had been on cabergoline 2.5 mg/d for the previous seven months. She complained of occasional nausea and dizziness, symptoms that were however milder by comparison with the side effects she had experienced whilst on bromocryptine.

Except for the various dopamine agonists, the patient did not receive any other medication. The patient’s compliance was confirmed by her husband.

On admission, physical examination showed induced galactorrhea. No signs of acromegaly or Cushing’s syndrome were present. PRL levels, measured twice while the patient was on cabergoline 2.5 mg/d, were 150 and 160 ng/ml, respectively. The rest of the pituitary function was normal. Androgen levels were found to be normal and serum estradiol was low (27 pmol/L, normal range 0.01-587 pmol/L). Ultrasound of the uterus and ovaries was normal and did not reveal any evidence of polycystic ovaries. Because of the low serum estradiol, we performed a Bone Mass Density measurement which showed osteopenia (T-score – 1.3). Measurement of bone turnover markers in blood and urine were normal, except for D-pyrilinks in the urine, a bone resorption marker, which was elevated. Blood count, erythrocyte sedimentation rate, renal and liver function tests, a chest x-ray, and urine osmolality were all within normal limits. An M.R.I. scan of the pituitary showed a microadenoma on the left lateral wing of the anterior pituitary, measuring 8 mm in diameter, similar in size to the one previously demonstrated. No sellar enlargement or extrasellar expansion were observed.

The existence of a mixed Growth Hormone (GH)-PRL secreting adenoma was ruled out by an IGF1 level which was within normal limits and an Oral Glucose Tolerance Test (OGTT) which suppressed GH sufficiently. In addition, whole body In111 octreotide scan was negative.

We also performed a Growth Hormone Releasing Hormone (GHRH) test to ascertain whether GH was blunted, but the result was negative (Figure 1). The diagnosis of a probable prolactinoma, resistant to dopamine agonists (bromocryptine, cabergoline, quinagolide), was consequently made. Based on the knowledge that dopamine resistance may sometimes
A case of a prolactinoma resistant to dopamine agonists

167A case of a prolactinoma resistant to dopamine agonists

...used to experience amenorrhea and galactorrhea. A thorough work-up revealed no other causes of hyperprolactinaemia besides the microprolactinoma. Over a period of 11 years, PRL levels remained stable as did the size of the adenoma, despite appropriate therapy with dopamine agonists. It is widely known that the growth rate of prolactinomas, especially microprolactinomas (defined as having a maximum diameter <1 cm) is generally slow. Resistant prolactinomas, however, represent the most severe aspect of this entity, have a tendency to grow faster and often result in increasing PRL levels if left untreated for long. This was not the case with our patient.

Dopamine agonist-resistant prolactinomas are characterized by their failure to normalize PRL levels and to decrease tumour size by ≥50% following appropriate treatment. Dopamine agonists act via dopamine G protein-coupled receptors, of which there are at least 5 subtypes (D_1–5). D_1 and D_5 receptors have a similar structure, are coupled to Gs proteins and stimulate adenylate cyclase, resulting in an increase of intracellular cAMP. D_2, D_3 and D_4 receptors share a similar structure, are coupled to Gi/o proteins, and their activation inhibits adenylate cyclase, opens potassium and closes calcium channels. The pituitary gland has an abundance of D_2 receptors and inhibition of PRL secretion is thought to be mediated through D_2 activation.

Positron Emission Tomography (PET) using high affinity dopamine agonists has been used to determine distribution and quantity of dopamine receptors in the brains of rodents and monkeys. PET has also been used in clinical studies to detect density and affinity of these receptors in human brains in vivo. Several mechanisms have been suggested to explain the phenomenon of prolactinomas’ resistance to dopamine agonists. Work with in vitro cell preparations of resistant prolactin secreting tumours has shown that a decreased number of D_2 receptors, due to a lower transcription level of the D_2 receptor gene, may be responsible for the resistance. A reduction of the Gi2 alpha and Gi/o proteins has also been observed and has been correlated with down-regulation of the D_2 receptor.

Influence the action of only some dopamine agonists, the patient was prescribed lysuride, a mixed D_2 agonist and D_1 antagonist, which was the only dopamine agonist on the Greek market that she had not been given. One month after lisuride initiation and on a gradually increasing regimen up to a maximum of 1mg/d (usual dose for prolactinomas 0.1-0.6 mg/d), the patient continued to present galactorrhea, and her PRL levels remained at 160 ng/ml.

Radiotherapy, either conventional or focused Gamma-knife, was not recommended in this relatively young patient due to the high possibility of inducing hypopituitarism. Transsphenoidal excision of the microadenoma was suggested, which she has so far refused.

DISCUSSION

During treatment with several different dopamine agonists — bromocryptine, quinagolide, cabergoline, lisuride (pergolide is not available in Greece) — at maximum or above maximum doses, the patient never achieved reduction in PRL levels and continued to experience amenorrhea and galactorrhea. A thorough work-up revealed no other causes of hyperprolactinaemia besides the microprolactinoma. Over a period of 11 years, PRL levels remained stable as did the size of the adenoma, despite appropriate therapy with dopamine agonists. It is widely known that the growth rate of prolactinomas, especially microprolactinomas (defined as having a maximum diameter <1 cm) is generally slow. Resistant prolactinomas, however, represent the most severe aspect of this entity, have a tendency to grow faster and often result in increasing PRL levels if left untreated for long. This was not the case with our patient.

Dopamine agonist-resistant prolactinomas are characterized by their failure to normalize PRL levels and to decrease tumour size by ≥50% following appropriate treatment. Dopamine agonists act via dopamine G protein-coupled receptors, of which there are at least 5 subtypes (D_1–5). D_1 and D_5 receptors have a similar structure, are coupled to Gs proteins and stimulate adenylate cyclase, resulting in an increase of intracellular cAMP. D_2, D_3 and D_4 receptors share a similar structure, are coupled to Gi/o proteins, and their activation inhibits adenylate cyclase, opens potassium and closes calcium channels. The pituitary gland has an abundance of D_2 receptors and inhibition of PRL secretion is thought to be mediated through D_2 activation.

Positron Emission Tomography (PET) using high affinity dopamine agonists has been used to determine distribution and quantity of dopamine receptors in the brains of rodents and monkeys. PET has also been used in clinical studies to detect density and affinity of these receptors in human brains in vivo. Several mechanisms have been suggested to explain the phenomenon of prolactinomas’ resistance to dopamine agonists. Work with in vitro cell preparations of resistant prolactin secreting tumours has shown that a decreased number of D_2 receptors, due to a lower transcription level of the D_2 receptor gene, may be responsible for the resistance. A reduction of the Gi2 alpha and Gi/o proteins has also been observed and has been correlated with down-regulation of the D_2 receptor.

Influence the action of only some dopamine agonists, the patient was prescribed lysuride, a mixed D_2 agonist and D_1 antagonist, which was the only dopamine agonist on the Greek market that she had not been given. One month after lisuride initiation and on a gradually increasing regimen up to a maximum of 1mg/d (usual dose for prolactinomas 0.1-0.6 mg/d), the patient continued to present galactorrhea, and her PRL levels remained at 160 ng/ml.

Radiotherapy, either conventional or focused Gamma-knife, was not recommended in this relatively young patient due to the high possibility of inducing hypopituitarism. Transsphenoidal excision of the microadenoma was suggested, which she has so far refused.

DISCUSSION

During treatment with several different dopamine agonists — bromocryptine, quinagolide, cabergoline, lisuride (pergolide is not available in Greece) — at maximum or above maximum doses, the patient never achieved reduction in PRL levels and continued to experience amenorrhea and galactorrhea. A thorough work-up revealed no other causes of hyperprolactinaemia besides the microprolactinoma. Over a period of 11 years, PRL levels remained stable as did the size of the adenoma, despite appropriate therapy with dopamine agonists. It is widely known that the growth rate of prolactinomas, especially microprolactinomas (defined as having a maximum diameter <1 cm) is generally slow. Resistant prolactinomas, however, represent the most severe aspect of this entity, have a tendency to grow faster and often result in increasing PRL levels if left untreated for long. This was not the case with our patient.

Dopamine agonist-resistant prolactinomas are characterized by their failure to normalize PRL levels and to decrease tumour size by ≥50% following appropriate treatment. Dopamine agonists act via dopamine G protein-coupled receptors, of which there are at least 5 subtypes (D_1–5). D_1 and D_5 receptors have a similar structure, are coupled to Gs proteins and stimulate adenylate cyclase, resulting in an increase of intracellular cAMP. D_2, D_3 and D_4 receptors share a similar structure, are coupled to Gi/o proteins, and their activation inhibits adenylate cyclase, opens potassium and closes calcium channels. The pituitary gland has an abundance of D_2 receptors and inhibition of PRL secretion is thought to be mediated through D_2 activation.

Positron Emission Tomography (PET) using high affinity dopamine agonists has been used to determine distribution and quantity of dopamine receptors in the brains of rodents and monkeys. PET has also been used in clinical studies to detect density and affinity of these receptors in human brains in vivo. Several mechanisms have been suggested to explain the phenomenon of prolactinomas’ resistance to dopamine agonists. Work with in vitro cell preparations of resistant prolactin secreting tumours has shown that a decreased number of D_2 receptors, due to a lower transcription level of the D_2 receptor gene, may be responsible for the resistance. A reduction of the Gi2 alpha and Gi/o proteins has also been observed and has been correlated with down-regulation of the D_2 receptor.
showed resistance to dopamine in this pathway as well. Therapeutic approaches to dopamine resistant prolactinomas include: a switch to another type of dopamine agonist, transphenoidal microsurgery and/or radiotherapy and new somatostatin analogues. It is well known that 84% of prolactinomas express somatostatin receptors (SSTR) type 1 (SSTR1), 63% express SSTR2 and 71% express SSTR5. It was recently demonstrated that somatostatin analogues, preferential for the SSTR5 receptor subtype, suppress PRL release in prolactinoma cell cultures by 30–40%. These data supported the idea of somatostatin receptor subtype-specific control of PRL secretion in such tumours, and were found to produce a significant inhibition of PRL release. Multiligand analogues have also been tried and proved to inhibit PRL release by both mixed GH/PRL adenomas and pure prolactinomas in vitro.

Recently a new somatostatin-dopamine hybrid molecule was introduced with potentially functional synergy on GH and PRL release. This molecule most likely constitutes a new therapeutic approach for mixed GH/PRL adenomas and possibly for resistant prolactinomas.

The usefulness of antiestrogen therapy in prolactinomas is controversial. It is known that prolactinomas express nuclear estrogen receptors at higher concentrations than other pituitary adenomas. In one study with 29 patients suffering from prolactinomas, it was shown that variables such as gender, age, menstrual status, exposure to dopamine agonists, PRL levels or tumour size were not predictive for the presence of estrogen receptors in prolactinomas. Caronti et al. showed that tamoxifen has an inhibitory effect on cell proliferation of human pituitary adenomas, independently of estrogen receptor expression. Rat models to study the effects of antiestrogens on pituitary adenomas are valuable for investigation of such treatment in human pituitary adenomas.

In conclusion, we describe a patient with a prolactinoma resistant to dopamine agonists and probable resistance of the mesolimbic dopaminergic system to dopamine agonists.
REFERENCES

17. Essential Psychopharmacology
